Tenderwize
Retour à la recherche

Open house discount agreements for active substance Tolvaptan, ATC G04BX21

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 29, 2028 · 498 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tolvaptan, ATC G04BX21

30/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

30 / 100

Complexité

20 / 100

Facteurs de risque

The buyer reserves the right to replace open house agreements with exclusive contracts during the term, which automatic...

No estimated value or volume is provided. Revenue potential is unclear, and the agreements may yield minimal discount-b...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Feb 29, 2028

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Conclusion of non-exclusive discount agreements for pharmaceuticals with active substance Tolvaptan (ATC G04BX21)
  • Open house model: all eligible pharmaceutical companies can join on uniform terms
Afficher le résumé complet

Open house non-exclusive discount agreements for the active substance Tolvaptan (ATC G04BX21) by AOK Rheinland-Pfalz/Saarland. All pharmaceutical companies can join on uniform terms from May 2026 to April 2028. No estimated value provided. The procedure is not a formal public procurement but published for transparency.

Risques

The buyer reserves the right to replace open house agreements with exclusive contracts during the term, which automatic...

No estimated value or volume is provided. Revenue potential is unclear, and the agreements may yield minimal discount-b...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Products must be authorized and marketable in Germany (listed in Lauer-Taxe or AMIce database)

Eligibility

  • Only pharmaceutical companies are eligible to participate

Administrative

  • Submission of signed contract documents either in paper (two copies, plus scan) or electronically with qualified electronic signature

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; all eligible pharmaceutical companies are accepted under uniform conditions.

Acheteur

Localisation

Eisenberg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE271900642

Activité

Health

Lots (1)

LOT-0001

Open house discount agreements for active substance Tolvaptan, ATC G04BX21

Non-exclusive rebate contracts for Tolvaptan products. Open to all pharmaceutical companies with authorized and marketable products in Germany. Uniform conditions, no negotiation. Maximum 24-month term, earliest start 01.05.2026. Buyer may replace with exclusive contracts during the term, terminating open house agreements automatically.

SuppliesEU fundedElectronic submission

Localisation

Eisenberg, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; all eligible pharmaceutical companies are accepted under uniform conditions.

Date limite

Deadline Feb 29, 2028

Détails de la procédure

Date de publication
15 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
178098-2026

Documents (1)

Appels d'offres similaires